



AMERICAN JOURNAL OF PHARMTECH RESEARCH

Journal home page: <http://www.ajptr.com/>

Synthesis of Bis-Amide and Hydrazone containing Derivatives of Malonic Acid and Hypophosphorousadducts of Acidhydrazones Derived from 2-[(N-Acetyl) 2, 5-Dichloroanilido] Acetohydrazide

Raj Narayan Sharma^{1*}, K. P. Sharma², S. N. Dikshit³

1. Department of Chemistry, BVM College of Tech. and Management

2. SMS Govt. Model Science College, (Jiwaji university) Gwalior-474002 (MP) India.

ABSTRACT

We synthesized a new series of bis-amide and hydrazone-containing derivatives of malonic acid and hypophosphorousadducts of acid hydrazones by the reaction of 2-[(N- (acetyl) 2, 5-dichloroanilido] acetohydrazide with various Carbonyl Compounds in 31 to 64% yield. Newly synthesized compounds have been tested for their anti-bacterial activity against gram positive bacteria *S.albus*, *S.aureus* and gram negative bacteria *E.coli* and *Pseudomonas piosineus*. The compound (1, 2, 3, 7, 10, 12, 15) shown significant activities and compound (4, 9, 13, 14, 17) have shown moderate activity. The same compounds were tested for their anti-fungal activity against *Candida albicans*, *Aspergillus niger* and *Alternaria alternata* at concentration of 30 mg/ml using Savored dextrose agar media. The compound (3, 5, 9, 11, 14) shown significant activities and compound (2, 4, 6, 13, 16) have shown moderate activity against *Candida albicans* and *Aspergillus niger*. All the other compounds did not show significant activity against the fungi at the concentration used.

Keywords: Malonic acid, bis-amides, acid hydrazides, hydrazones, hypo phosphorous adducts

*Corresponding Author Email: rajnarayan1974@gmail.com

Received 25 March 2012, Accepted 9 April 2012

Please cite this article in press as: Sharma RN. *et al.*, Synthesis of Bis-Amide and Hydrazone containing Derivatives of Malonic Acid and Hypophosphorousadducts of Acidhydrazones Derived from 2-[(N-Acetyl) 2, 5-Dichloroanilido] Acetohydrazide. American Journal of PharmTech Research 2012.

INTRODUCTION:

Acid hydrazones and their condensation products possessing an azometine -NHN=CH- Proton constitute an important class of compounds for new drug development. In the past several years, numerous compounds with diverse structural features have been reported. Therefore, many researchers have synthesized these compounds as target structures and evaluated their biological activities. Hydrazides, hydrazones and their adducts have displayed diverse range of biological properties such as potential biological activities¹⁻¹², anti-viral¹³⁻¹⁹, anti-tuberculosis²⁰, anti-tumor²¹⁻²⁴, cardiovascular²⁵, anti-convulsant²⁶⁻²⁸, anti-leprotic²⁹, anti-malarial³⁰⁻³¹, vasodilator activities³², anti- Inflammatory³³⁻³⁷. Therapeutic protocols for the treatment of HIV infection are mainly based on the combined use of reverse transcriptase, protease, and more recently, of cell fusion and entry inhibitors. Although drugs targeting reverse transcriptase and protease are in wide use and have shown effectiveness, the rapid emergence of resistant variants, often cross-resistant to the members of a given class, limits the efficacy of existing antiretroviral drugs. Therefore, it is critical to develop new agents directed against alternate sites in the viral life cycle, anti-cancer³⁸⁻⁴⁵ and anti-HIV⁴⁶⁻⁵². Moreover, many selectively chloro-substituted organic compounds show peculiar pharmacological and agrochemical properties. The work reported herein was aimed at the preparation of some new hypophosphorous adducts of acid hydrazones with anticipated biological activities.

MATERIALS AND METHODS:

Anhydrous solvents and all reagents were purchased from, Sigma-Aldrich, B.D.H., Excel-R, Extra pure E. Merk quality, Acros or Carlo Erba. Reactions involving air- or moisture-sensitive compounds were performed under a nitrogen atmosphere using oven-dried glassware and syringes to transfer solutions. Melting points (m.p.) were determined using an electro thermal melting point or a Köfler apparatus and are uncorrected. Infrared (IR) spectra were recorded as thin films or nujol mulls on KBr plates with a Perkin-Elmer-781 IR or 983 -Spectrophotometer and are expressed in ν (cm^{-1}). Nuclear magnetic resonance spectra (¹H-NMR) were determined in CDCl₃/DMSO-d₆ (in 3/1 ratio) or DMSO-d₆ and were recorded on a Varian XL-200 (200 MHz) or a Varian VXR-300 (300 MHz). Chemical shifts (δ scale) are reported in parts per million (ppm) downfield from tetramethylsilane (TMS) used as internal standard. Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quadruplet; m, multiplet; brs, broad singlet; dd, double doublet. The assignment of exchangeable protons (-OH and -NH) was confirmed by addition of D₂O. Analytical thin-layer chromatography (TLC) was carried out

on Merck silica gel, F-254 plates. For flash chromatography Merck Silica gel-60 was used as stationary phase with a particle size 0.040-0.063 mm (230-400 mesh ASTM). Elemental analyses were performed on a Perkin-Elmer-2400 spectrometer, and were within $\pm 0.8\%$ of the theoretical values.

Synthesis of Ethyl-2-(2, 5-dichloroanilido) ethanoate [1]:

A mixture of 2, 5-dichloroaniline (10ml) and diethylmalonate (20ml) was refluxed for forty five minutes in a round bottomed flask fitted with an air condenser of such a length (14") that ethanol formed escaped and diethylmalonate flowed back into the flask. Contents were cooled, ethanol (30 ml) was added, when malon-2, 5-dichlorodianilide separated out. It was filtered under suction. The filtrate was poured on to crushed ice (Ca160g) and stirred when ethyl-2-(2, 5-dichloroanilido) ethanoate precipitated as green mass. On recrystallization from aqueous ethanol (50%), ester was obtained as white crystals.

Synthesis of Ethyl-2-[(N-acetyl) 2, 5- dichloroanilido] ethanoate [2]:


Acetyl chloride (4.74 gm; 0.06 mol), dioxane (6 ml), Ethyl-2-(2, 5-dichloroanilido) ethanoate (16.56 gm; 0.06 mol) and triethylamine (5.7 gm; 0.06 mol) were placed in a round bottomed flask carrying reflux condenser having calcium chloride guard tube. The contents were heated on a boiling water bath for two hours and kept over night when triethylamine hydrochloride separated. It was filtered under suction and the filtrate was poured on to crushed ice (Ca180 g) and stirred when ethyl-2-[(N-acetyl) 2, 5-dichloroanilido] ethanoate separated or solid. It was filtered under suction, dried and purified by recrystallization from aqueous methanol (1:1) in white crystals.

Synthesis of 2-[(N-acetyl) 2, 5- dichloroanilido] acetohydrazide [3]:

Ethyl-2-[(N-acetyl) 2, 5-dichloroanilido] ethanoate (9.54 gm; 0.03 mol), ethanol (10 ml) and hydrazine hydrate (15 ml; 80%) were mixed together and stirred for thirty five minutes. 2-[(N-acetyl) 2, 5-dichloroanilido] acetohydrazide was filtered under suction and recrystallised from ethanol in white crystals.


Synthesis of 2-[(N-acetyl) 2, 5-dichloroanilido] acetohydrazones [4]:

2-[(N-acetyl) 2, 5-dichloroanilido] acetohydrazide (0.001 mol) and (0.001 mol) of aromatic aldehyde or ketone [such as benzaldehyde] dissolve in absolute alcohol and added 2-drops of conc. H_2SO_4 and stirred for 25 minutes. It was filtered under suction and recrystallised from hot ethanol. Color: Silver white.



SCHEME -I

Where



- (i) Quantity of acidhydrazone = 0.001 mol.
- (ii) Quantity of hypophosphorous acid = 2.0 g
- (iii) Quantity of absolute alcohol = 25 ml.
- (iv) Hours of heating = 3.5 hours.
- (v) Solvent for crystallization - ethanol.





CHART – I

[Mechanism: formation of new acid hydrazones]

Table-I: Reaction conditions for the formation of hypophosphorous adducts of acidhydrazones.

Sr. No.	Acidhydrazones	Quantity of Acidhydrazone(g)	Adducts		MP (°C)	Yield (%)	Formula weight	Molecular formula	Colour
			R ₁	R ₂					
01.	Benzaldehyde-2-[(N-acetyl) 2, 5-dichloroanilido] acetohydrazone	0.458	H	Ph	268	60	458	C ₁₈ H ₁₉ O ₅ N ₃ Cl ₂ P	White
02.	Vanilline-2-[(N-acetyl) 2, 5-dichloroanilido] acetohydrazone	0.504	H	Ph $\begin{cases} \text{OMe} (3) \\ \text{OH} (4) \end{cases}$	257	59	504	C ₁₉ H ₂₁ O ₇ N ₃ Cl ₂ P	White
03.	5-chloro Salicylaldehyde-2-[(N-acetyl) 2, 5-dichloro anilido] acetohydrazone	0.509.5	H	Ph $\begin{cases} \text{OH} (2) \\ \text{Cl} (5) \end{cases}$	241	52	509.5	C ₁₈ H ₁₉ O ₆ N ₃ Cl ₃ P	White
04.	5-Bromo Salicylaldehyde-2-[(N-acetyl) 2, 5-dichloroanilido] acetohydrazone	0.554	H	Ph $\begin{cases} \text{OH} (2) \\ \text{Br} (5) \end{cases}$	228	55	554	C ₁₈ H ₁₉ O ₆ N ₃ Cl ₂ BrP	Silver White
05.	2-Nitro Vanilline-2-[(N-acetyl) 2, 5-dichloroanilido]acetohydrazone	0.553	H	Ph $\begin{cases} \text{NO}_2 (2) \\ \text{OCH}_3 (3) \\ \text{OH} (4) \end{cases}$	230	64	553	C ₁₉ H ₂₁ O ₉ N ₄ Cl ₂ P	Cream
06.	O-Nitrobenzaldehyde-2- [(N-acetyl) 2, 5-dichloroanilido] acetohydrazone	0.504	H	Ph - NO ₂ (2)	242	53	504	C ₁₈ H ₁₃ O ₇ N ₄ Cl ₂ P	White
07.	2-Nitro-5-Bromo Vanilline-2-[(N-acetyl) 2, 5-dichloroanilido)] acetohydrazone	0.629	H	Ph $\begin{cases} \text{NO}_2 (2) \\ \text{OMe} (3) \\ \text{OH} (4) \\ \text{Br} (5) \end{cases}$	259	56	629	C ₁₉ H ₂₀ O ₉ N ₄ Cl ₂ BrP	Cream
08.	3,5-dichloro-2-hydroxy benzaldehyde-2-[(N-acetyl) 2, 5-dichloroanilido] acetohydrazone	0.544	H	Ph $\begin{cases} \text{OH} (2) \\ \text{Cl} (3) \\ \text{Cl} (5) \end{cases}$	246	62	544	C ₁₈ H ₁₈ O ₆ N ₃ Cl ₄ P	White
09.	3-Nitro- 6-hydroxy acetophenone-2-[(N-acetyl) 2, 5-dichloro anilido] acetohydrazone	0.534	Me	Ph $\begin{cases} \text{NO}_2 (3) \\ \text{OH} (6) \end{cases}$	255	51	534	C ₁₉ H ₂₁ O ₈ N ₄ Cl ₂ P	Cream

10.	Acetone-2-[(N-acetyl) 2, 5-dichloroanilido] acetohydrazone	0.410	Me	Me	259	47	410	C ₁₄ H ₁₉ O ₅ N ₃ Cl ₂ P	Cream
11.	2-Chlorobenzaldehyde-2-[(N-acetyl) (2, 5-dichloroanilido)] acetohydrazone	0.493.5	H	Ph – Cl (2)	227	60	493.5	C ₁₈ H ₁₉ O ₅ N ₃ Cl ₃ P	White
12.	4-NN-bis-2'-cyanoethylamino benzaldehyde-2-[(N-acetyl) 2, 5-dichloroanilido] acetohydrazone	0.580	H	Ph – N – (CH ₂ – CH ₂ – CN) ₂	241	64	580	C ₂₄ H ₂₇ O ₅ N ₆ Cl ₂ P	Light brown
13.	2-Methyl-4-N-N-bis-2'-cyanoethyl aminobenzaldehyde [(N-acetyl) 2, 5-dichloroanilido] aceto hydrazone	0.594	H	Ph $\left\langle \begin{array}{l} \text{CH}_3 \text{ (2)} \\ \text{N(CH}_2 - \text{CH}_2 - \text{CN)}_2 \end{array} \right.$	256	44	594	C ₂₅ H ₂₉ O ₅ N ₆ Cl ₂ P	Brown
14.	2-Methoxy-4-N-N-bis-2'-cyanoethylamino benzaldehyde [(N-acetyl) 2, 5-dichloro anilido] acetohydrazone	0.610	H	Ph $\left\langle \begin{array}{l} \text{OCH}_3 \text{ (2)} \\ \text{N(CH}_2 - \text{CH}_2 - \text{CN)}_2 \end{array} \right.$	248	56	610	C ₂₇ H ₂₇ O ₆ N ₆ Cl ₂	Brown
15.	Acetophenone-2-[(N-acetyl) 2, 5-dichloroanilido] acetohydrazone	0.472	Me	Ph	248	54	472	C ₁₉ H ₂₁ O ₅ N ₃ Cl ₂ P	White
16.	Salicylaldehyde-2-[(N-acetyl) 2, 5-dichloroanilido] aceto hydrazone	0.475	H	Ph – OH (2)	259	50	475	C ₁₈ H ₂₀ O ₆ N ₃ Cl ₂ P	White
17.	Anisicaldehyde-2-[(N-acetyl) 2, 5-dichloroanilido] acetohydrazone	0.489	H	Ph – OCH ₃ (2)	238	64	489	C ₁₉ H ₂₂ O ₆ N ₃ Cl ₂ P	Yellow
18.	β-Ionone-2-[(N-acetyl) (2, 5-dichloroanilido)] acetohydrazone	0.546	Me		218	31	546	C ₂₄ H ₃₅ O ₅ N ₃ Cl ₂ P	Buff

Biological evaluation

Anti-bacterial activity

Newly synthesized hypophosphorousadducts of acidhydrazones were screened for their anti-bacterial activity against the gram positive bacteria *S. albus*, *S. aureus* and gram negative bacteria *E.coli* and *Pseudomonas piosineus* by agar plate disc diffusion method at 30 µg/mL concentration. Ampicillin and tetracycline were used as a reference compounds.

Anti-fungal activity

The same compounds were tested for their antifungal activity against *Candida albicans*, *Aspergillus niger* and *Alternaria alternata* at concentration of 30 mg/ml using Savored dextrose agar media.

RESULTS AND DISCUSSION

Hypophosphorousadducts of various acidhydrazones have been synthesized by the reaction of 2-[N- (acetyl) 2, 5-dichloroanilido] acetohydrazide with various Carbonyl Compounds in 31 to 64% yield. Hydrazonephosphorousadducts are white, brown and yellow colour solids, having high melting points. The structure of all the compounds are confirmed by IR, NMR, and Mass spectral data and are further supported by correct elemental analysis. Some characteristics of the synthesized compounds are shown in table. Analytical and spectral data confirmed the structures of the new compounds.

Synthesis of Ethyl-2-(2, 5-dichloroanilido) ethanoate [1]:

Yield: 83%, M. P.: 90°C, M. W.: 276. Anal. Calculation for $C_{11}H_{11}N_1O_3Cl_2$: Found: C 47.7, H: 4.0, O: 17.2, N: 5.1, Cl: 25.4, Calcd. C: 47.8, H: 4.0, O: 17.4, N: 5.1, Cl: 25.7. IR [KBr] $V_{max} \text{ cm}^{-1}$: 1665-1660 [C=O diketone], 1290 [-O- Ester], 760-755 [2,5-disubstituted benzene], 1090 [C-Cl Stretching], 1590, 1520, 1440 [C=C ring stretching], 3150 [N-H Stretching], 3040[C-H aromatic], 1330-1320 [C-H Stretching]. PMR (DMSO): δ 4.45 (2H, s, CO-CH₂-CO), 4.0 (2H, s, NH₂), 7.4-8.7 (3H, m, Ar-H), 9.4 (1H, s, CO-NH D₂O exchangeable), 10.4 [1H, s, Ar-NH D₂O exchangeable].

Synthesis of Ethyl-2-[(N-acetyl) 2, 5- dichloroanilido] ethanoate [2]:

Yield = 77 %, MP = 96°C Analytical calculation for $C_{13}H_{13}O_4N_1Cl_2$: [FW = 318] , Calculated: N 02.95 , C 45.64, H 03.38 , O 13.50 , Cl 15.00 , Found : N 02.94, C 45.62 , H 03.37 , O 13.52 , Cl 15.02. IR [KBr] $V_{max} \text{ cm}^{-1}$: 1720 [C=O diketone], 1310 [-C-O- Ester], 765 [2,5- disubstituted benzene], 1095 [C-Cl Stretching], 1590, 1525 , 1440 [C=C Ring stretching], 3160 [N-H Stretching], 3040[C-H aromatic], 1330-1325 [C-H Stretching]. PMR

(DMSO): δ 4.42 [2H, s, CO-CH₂-CO], 4.1 [2H, s, NH₂], 7.2-8.5 [3H, m, Ar-H], 9.5 [1H, s, CO-NH D₂O exchangeable], 10.8 [1H, s, Ar-NH D₂O exchangeable].

Synthesis of 2-[(N-acetyl) 2, 5- dichloroanilido] acetohydrazide [3]:

Yield; 74%, MP = 178°C, MW 304: Analytical calculation for C₁₁ H₁₁ N₃ O₃ Cl₂ : Calculated ; N 09.04 ,C 41.32 ,H 03.01 ,O 10.33, Cl 15.28, Found; N 09.01, C 41.30, H 03.00, O 10.31, Cl 15.27. IR [KBr] V_{max} cm⁻¹: 3165 [N-H Stretching], 3050 [C-H aromatic], 1670 [C=O diketone], 1430 [C-Cl aromatic], 1595, 1520, 1445 [C=C ring stretching]. PMR (DMSO): δ 4.44 (2H, s, CO-CH₂-CO), 4.4 (2H, s, NH₂), 7.3-8.5 (3H, m, Ar-H), 9.5 (1H, s, CO-NH D₂O exchangeable), 10.5 (1H, s, Ar-NH D₂O exchangeable).

Synthesis of 2-[(N-acetyl) 2, 5-dichloroanilido] acetohydrazones [4]:

Yield: 86%, M.P= 218 °C, F.W: 392, Analytical calculation for C₁₈H₁₅O₃N₃Cl₂, Calculated: N 12.04, C 54.85, H 03.71, O 09.14, Cl 20.28, Found: N 11.98, C 54.82, H 03.70, O 10.31, Cl 20.26. IR Absorption band (cm⁻¹): 3160 (N-H stretching), 2960–2975 (C-H aliphatic), 1665–1660 (C=O Ketone), 795–780 (C-Cl Stretching), 765 (2, 5-disubstituted benzene). NMR Spectra: (δ DMSO), 2.20(2 H, s, CH₂), 4.22(1 H, s, NH), 6.96–7.2 (10 H, m, ArH. Synthetic strategy has been out lined in scheme-I. Mechanism for the formation of acid hydrazones is given in chart-I. Synthesized compounds have been tested for their antibacterial activity against gram positive bacteria *S. albus*, *S. aureus* and gram negative bacteria *E.coli* and *Pseudomonas piosineus*. The compound (1, 2, 3, 7, 10, 12, 15) shown significant activities and compound (4, 9, 13, 14, 17) have shown moderate activity. The same compounds were tested for their antifungal activity against *Candida albicans*, *Aspergillus niger* and *Alternaria alternata* at concentration of 30 mg/mL using savored dextrose agar media. The compound (3, 5, 9, 11, 14) shown significant activities and compound (2, 4, 6, 13, 16) have shown moderate activity against *Candida albicans* and *Aspergillus niger*. All the other compounds did not show significant activity against the fungi at the concentration used.

CONCLUSIONS

Newly synthesized compounds have been tested for their **antibacterial activity** against gram positive bacteria *S. albus*, *S. aureus* and gram negative bacteria *E.coli* and *Pseudomonas piosineus* by agar plate disc diffusion method at 30 μ g/mL concentration. Ampicillin and tetracycline were used as a reference compounds. The compound (1, 2, 3, 7, 10, 12, 15) shown significant activities and compound (4, 9, 13, 14, 17) have shown moderate activity. The same compounds were tested for their **antifungal activity** against *Candida albicans*, *Aspergillus niger*

and *Alternaria alternata* at concentration of 30 albicans and *Aspergillus niger*. All the other compounds did not show significant activity mg/mL using Savored dextrose agar media. The compound (3, 5, 9, 11, 14) shown significant activities and compound (2, 4, 6, 13, 16) have shown moderate activity against *Candida* against the fungi at the concentration used.

ACKNOWLEDGEMENTS

The authors are thankful to Director, C.D.R.I. Lucknow, for elemental analysis, Director, D.R.D.E. Gwalior, for spectral studies, and Director, Cancer Hospital and Research Institute, G.R. Medical College and Birla Institute of Medical Research, Gwalior, for biological activities. We are also grateful to principal SMS Government Model Science College, Gwalior, for providing research facilities.

REFERENCES

1. Kutyrev, A, Kappe T. Methanetricarboxylates as Key Reagents for the Simple Preparation of Heteroarylcarboxamides with Potential Biological Activity. Part 1. Reaction of Methanetricarboxylates with Indoline and 1, 2, 3, 4-Tetrahydroquinoline. J Heter Chem 1997, 34, 969-972.
2. Nishino H, Ishida K, Hashimoto H, Kurosawa K. Manganese (III)-Mediated Oxidative Radical Cyclization 3. Synthesis of 3-Azabicyclo [3, 3, 0]-octan-2-ones and Related Compounds in the Reaction of 1, 1, 6, 6-Tetraarylhexas-1, 5-dienes with N,N'-Disubstituted Malonamides. Synthesis 1996, 888-896.
3. Sotriffer CA, Ni H, McCammon AJ. HIV-1 Integrase inhibitor interactions at the active site: prediction of binding modes unaffected by crystal packing. J Am Chem Soc. 2000, 122, 6136-6137.
4. Sechi M, Angotzi G, Dallochio R, Dessì A, Carta F, Sannia L, Mariani A, Fiori S, Sanchez T, Movsessian L, Plasencia C, Neamati N. Design and synthesis of novel dihydroxyindole-2-carboxylic acids as HIV-1 integrase inhibitors. Antiv Chem Chemother 2004, 15, 67-81.
5. Ni H, Sotriffer CA, McCammon JA. Ordered water and ligands mobility in the HIV-1 integrase-5CITEP complex: a molecular dynamics study. J Med Chem 2001; 44:3043-3047.
6. Barreca ML, Lee KW, Chimirri A, Briggs J.M. Molecular dynamics studies of the wildtype and double mutant HIV-1 integrase complexed with the 5CITEP inhibitor: Mechanism for inhibition and drug resistance. Biophys J 2003, 84, 1450-1463.
7. Zeinalipour-Loizidou, E.; Nicolaou, C.; Nicolaides, A.; Kostrikis, L. G. HIV-1 Integrase: From Biology to Chemotherapeutics. Curr. HIV Res. 2007, 5, 365-388.

8. Semenova, E. A.; Marchand, C.; Pommier, Y. HIV-1 integrase inhibitors: update and perspectives. *Adv. Pharmacol.* 2008, 56, 199-228.
9. Sechi, M.; Bacchi, A.; Carcelli, M.; Compari, C.; Duce, E.; Fiscaro, E.; Rogolino, D.; Gates, P.; Derudas, M.; Al-Mawsawi, L. Q.; Neamati, N. From Ligand to Complexes: Inhibition of Human Immunodeficiency Virus Type 1 Integrase by β -Diketo Acid Metal Complexes. *J. Med. Chem.* 2006, 49, 4248-4260.
10. Grimm, J.; Harrington, P.; Heidebrecht, R., Jr.; Miller, T.; Otte, K.; Siliphaivanh, P.; Sloman, D.; Stanton, M.; Wilson, K.; Witter, D.; Kattar, S.; Tempest, P. Preparation of modified malonates, particularly 2-[4-[[[(2-aminophenyl)amino]carbonyl]phenyl]-N,N'-disubstituted malonamides and related derivatives, as histone deacetylase inhibitors useful for treating neoplasm and other proliferative diseases. [PCT Int. Appl., WO 2007002248 2007].
11. Schock BC, Sweet DG, Ennis M, Warner JA, Young IS, Halliday HL. Oxidative stress and increased type-IV collagenase levels in bronchoalveolar lavage fluid from newborn babies. *Pediatr Res* 2001; 50(1):29 – 33.
12. Pantke U, Volk T, Schmutzler M, Kox WJ, Sitte N, Grune T. Oxidized proteins as a marker of oxidative stress during coronary heart surgery. *Free Radic Biol Med* 1999; 27 (9–10): 1080–6.
13. Neamati N, Marchand, C, Pommier Y. HIV-1 integrase inhibitors: past, present, and future. In *Advances in Pharmacology*; Academic Press: San Diego, USA, 2000; 49: 147-165.
14. Jahagirdar JA, Patil BG, Havinale BR. Cobalt (II), nickel (II), and copper (II) Complexes of malonoanilic acidhydrazones. *Indian J Chem A: Inorg Phys Theor Anal* 1990; 29A:924-926.
15. David L, Rusu M, Cozar O, Rusu D, Todica M, Balan C. Spectroscopic and magnetic investigations of some transition metal complexes with N-4-methoxyphenyl-N-4-chlorobenzoyl hydrazide as ligand. *J. Mol. Struct.* 1999; 482-483:149-152.
16. Shulgin VF, Pevzner NS, Zub VY, Strizhakova NG, Maletin YA. The synthesis and structure of nickel (II) and copper (II) complexes with N, N-dimethyl-N'-(2, 4-dichlorophenoxy)acetyl hydrazine. *Inorg Chem Comm* 2001, 3, 134-137.
17. Falchi, A, Porcheddu A, Taddei M. 4-(4,6-Dimethoxy[1,3,4]triazin-2-yl)-4-methylmorpholinum chloride (DMTMM): a valuable activating agent for carboxylic acids in solution, liquid and solid phase synthesis. *Acros Org. Acta* 2001;8:8-10.
18. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H, Davies DR. Structure of the HIV-1 integrase catalytic domain complexed with

- an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. USA 1999, 96, 13040-13043.
19. Neamati N, Marchand C, Pommier Y. HIV-1 integrase inhibitors: past, present, and future. In *Advances in Pharmacology*; Academic Press: San Diego, USA, 2000; volume 49, pp. 147-165.
 20. R. Cavier and R. Rips, Dihydrazides, a New Class of Anthelmintics (Fac. Pharm, Paris), *J. Med. Chem*, 1965;8 (5):706-8.
 21. S.Güniz Küçükgülzel, Adil Mazi Fikrettin Sahin, Suzan Öztürk, James Stables Synthesis and biological activities of diflunisal hydrazide–hydrazones”, *Eur J Medicinal Chemistry*, 2003;38(11-12):1005-1013.
 22. Céline Loncle, Jean Michel Brune¹, Nicolas Vida¹ Michel Dherbomez, Synthesis and antifungal activity of cholesterol-hydrazone derivatives, *Eur J Medicinal Chemistry* 2004;39(12):1067–1071.
 23. Amos B Smith; Synthesis and biological evaluation of phorboxazole congeners leading to the discovery and preparative-scale synthesis of (+)-chlorophorboxazole a possessing picomolar human solid tumor cell growth inhibitory activity. *J Org Chem* 73:1201-8; USA
 24. Sreeja PB, MR. Prathapachandra Kurup. Synthesis and spectral characterization of ternary complexes of oxovanadium(IV) containing some acid hydrazones and 2,2'-bipyridine . *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* ; 2005;61(1):331-336.
 25. Uchida K. Role of reactive aldehyde in cardiovascular diseases. *Free Radic Biol Med* 2000; 28: 1685– 96.
 26. Sevim Rollas , and S. G. Küçükgülzel, Biological Activities of Hydrazone Derivatives, *Molecules* 2007;12(8):1910-1939.
 27. Koçyiğit-Kaymakçioğlu Bedia, Oruç Elçin Unsalan Seda Kandemirli Fatma Shvets Nathaly Rollas Sevim Anatholy Dimoglo, Synthesis and characterization of novel hydrazide–hydrazones and the study of their structure–antituberculosis activity. *Eur J Medicinal Chemistry* 2006; 41(11):1253–1261.
 28. Shivananda Wagle. Synthesis of some new 4-styryltetrazolo[1,5-a]quinoxaline and 1-substituted-4-styryl[1,2,4]triazolo[4,3-a]quinoxaline derivatives as potent anticonvulsants. *Eur J Med Chem* 44: 1135-43, India

29. Andrea Masunari, Leoberto Costa Tavares, A new class of nifuroxazide analogues: Synthesis of 5-nitrothiophene derivatives with antimicrobial activity against multidrug resistant *Staphylococcus aureus*, *Bioorganic & Medicinal Chemistry* 2007;15(12):4229–4236.
30. Dharmarajan Sriram, Perumal Yogeewari, Kasinathan Madhu, Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones. *Bioorganic & Medicinal Chemistry Letters* 2005;15(20):4502–4505.
31. Atanas Bijev' Synthesis and in vitro Evaluation of New Hydrazones as Pyrrole Derivatives with Anti-tubercular Activity, *Arzneimittelforschung* 2009; 59(1): 34-41.
32. Alexandre G. Silva, Gisele Zapata-Sudo, Arthur E. Kummerle, Carlos A.M. Fraga, Eliezer J. Barreiro, Roberto T. Sudo, 'Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues' *Bioorganic & Medicinal Chemistry*, 16 May 2005, Volume 13, Issue 10, Pages 3431–3437.
33. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoff- 36 I. Dalle-Donne et al. / *Clinica Chimica Acta* 329 (2003) 23–38 man J, et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. *Free Radic Biol Med* 2002; 33(3):311 –22
34. Amal AM Eissa. Synthesis, biological evaluation and docking studies of novel benzopyranone congeners for their expected activity as anti-inflammatory, analgesic and antipyretic agents. *Bioorg Med Chem* 17:5059-70; Egypt.
35. Telci A, Cakatay U, Kayali R, Erdogan C, Orhan Y, Sivas A, et al. Oxidative protein damage in plasma of type 2 diabetic patients. *Horm Metab Res* 2000; 32(1):40– 3.
36. Anas JM Rasras. Synthesis and antimicrobial activity of cholic acid hydrazone analogues. *Eur J Med Chem* 45:2307-13; Jordan
37. Dharmarajan Sriram. Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones. *Bioorg Med Chem Lett* 15:4502-5; India
38. Scior T, Garces-Eisele SJ. Isoniazid is Not a Lead Compound for its Pyridyl Ring Derivatives, Isonicotinoyl Amides, Hydrazides, and Hydrazones: A Critical Review, *Curr Med Chem* 2006;13:2205-2219.
39. Yves L. Janin, Antituberculosis drugs: Ten years of research, *Bioorganic & Medicinal Chemistry* 2007; 15(7):2479–2513.
40. Nuray Ulusoy, Aysel Gürsoy, Gülten Ötük, Synthesis and antimicrobial activity of some 1,2,4-triazole-3-mercaptoacetic acid derivatives, *Il Farmaco*, 2001;56(12):947–952.
41. Linhong Jin, Jiang Chen, Baoan Song, Zhuo Chen, Song Yang, Qianzhu Li, Deyu Hu, Ruiqing Xu, 'Synthesis, structure, and bioactivity of N'-substituted benzylidene-3,4,5-

- trimethoxybenzohydrazide and 3-acetyl-2-substituted phenyl-5-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1,3,4-oxadiazole derivatives', *Bioorganic & Medicinal Chemistry Letters* 2006;16 (19):5036–5040.
42. I. Čaleta, M. Grdiša, D. Mrvoš-Sermek, M. Cetina, V. Tralić-Kulenović, K. Pavelić, G. Karminski-Zamola, Synthesis, crystal structure and antiproliferative evaluation of some new substituted benzothiazoles and styrylbenzothiazoles, *Il Farmaco*, April 2004, Volume 59, Issue 4, Pages 297–305.
43. Geoffrey Wells, Tracey D. Bradshaw, Patrizia Diana, Angela Seaton, Dong-Fang Shi, Andrew D. Westwell, Malcolm FG. Stevens, Antitumour benzothiazoles. Part 10: The synthesis and antitumour activity of benzothiazole substituted quinol derivatives, *Bioorganic & Medicinal Chemistry Letters*, 2000; 10(5):513–515.
44. Nalan Terzioglu, Aysel Gürsoy, Synthesis and anticancer evaluation of some new hydrazone derivatives of 2,6-dimethylimidazo[2,1-b][1,3,4]thiadiazole-5-carbohydrazide, *Eur J Medicinal Chemistry* 2003; 38(7–8):781–786.
45. Hall IH. Cytotoxicity of imides-N-alkyl semicarbazones, thiosemicarbazones, acetylhydrazones and related derivatives", *Anticancer Drugs* 6:147-53; USA
46. Seena EB, Nancy Mathew, Mini Kuriakos MR. Prathapachandra Kurup; *Polyhedron*, 2008; 27(5):1455-1462.
47. Mario Sechi, Ugo Azzena, Maria Paola Delussu, Roberto Dallochio, Alessandro Dessì, Alessia Cosseddu, Nicolino Pala, Nouri Neamati. Design and synthesis of bis-amide and hydrazide-containing derivatives of malonic acid as potential HIV-1 integrase inhibitors. *Molecules* 2008;13:2442-2461.
48. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. *Nat Rev Drug Discov* 2005; 4:236-248.
49. Neamati, N. Patented small molecule inhibitors of HIV-1 integrase: a ten-year saga. *Expert Opin Ther Pat* 2002;12:709-724.
50. Cotelle P. Patented HIV-1 integrase inhibitors (1998-2005). *Recent Patents Anti-Infect. Drug Disc* 2006;1:1-15.
51. Wang Y, Serradell N, Bolos J, Rosa E. MK-0518, HIV integrase inhibitor. *Drugs Fut.* 2007; 32:118-122.
52. Pais GCG, Burke TR. Novel aryl diketo-containing inhibitors of HIV-1 integrase. *Drugs Fut.* 2002; 27:1101-1111.